A PRO-cision Medicine Intervention to Personalize Cancer Care Using Patient-Reported Outcomes: Intervention Development and Feasibility-Testing.

Purpose PRO-cision medicine refers to personalizing care using patient-reported outcomes (PROs). We developed and feasibility-tested a PRO-cision Medicine remote PRO monitoring intervention designed to identify symptoms and reduce the frequency of routine in-person visits. Methods We conducted focus groups and one-on-one interviews with metastatic breast ( n = 15) and prostate ( n = 15) cancer patients and clinicians ( n = 10) to elicit their perspectives on a PRO-cision Medicine intervention’s design, value, and concerns. We then feasibility-tested the intervention in 24 patients with metastatic breast cancer over 6-months. We obtained feedback via end-of-study surveys (patients) and interviews (clinicians). Results Focus group and interview participants reported that remote PRO symptom reporting could alert clinicians to issues and avoid unneeded/unwanted visits. However, some patients did not perceive avoiding visits as beneficial. Clinicians were concerned about workflow. In the feasibility-test, 24/236 screened patients (10%) enrolled. Many patients were already being seen less frequently than monthly ( n = 97) or clinicians did not feel comfortable seeing them less frequently than monthly ( n = 31). Over the 6-month study, there were 75 total alerts from 392 PRO symptom assessments (average 0.19 alert/assessment). Patients had an average of 4 in-person visits (vs. expected 6.5 without the intervention). Patients ( n = 19/24) reported high support on the end-of-study survey, with more than 80% agreeing with positive statements about the intervention. Clinician end-of-study interviews ( n = 11/14) suggested that PRO symptom monitoring be added to clinic visits, rather than replacing them, and noted the increasing role of telemedicine. Conclusions Future research should explore combining remote PRO symptom monitoring with telemedicine and in-person visits.